Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Randomized Blinded Study to Evaluate SYN023 Compared to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies in Adults With Different Rabies Exposure Risks

NCT03961555 is registered in ClinicalTrials.gov with Synermore Biologics Co., Ltd. as lead sponsor.

NCT NCT03961555
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03961555 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Randomized Blinded Study to Evaluate SYN023 Compared to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies in Adults With Different Rabies Exposure Risks
Lead sponsor
Synermore Biologics Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
September 3, 2019
Completion date
December 23, 2021
Enrollment
448 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

rabies